<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40623210</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Days at Home Up to 30 Days After Robotic Versus Laparoscopic Colorectal Surgery.</ArticleTitle><Pagination><StartPage>1207</StartPage><EndPage>1214</EndPage><MedlinePgn>1207-1214</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003861</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">"Days at home up to 30 days" is a novel patient-centered outcome metric that measures the number of days patients spend at home 30 days after surgery. It encompasses inpatient stay from index admission, interhospital transfers and step-downs, and readmissions across different hospitals.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Comparison of days at home up to 30 days and established outcome metrics after robotic versus 3-dimensional laparoscopic colorectal surgery.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study of consecutive patients.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Townsville University Hospital and Mater Private Hospital, Townsville, Queensland, Australia.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Adult patients undergoing robotic and 3-dimensional laparoscopic colorectal surgery.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Days at home up to 30 days, 30-day readmission rate, index admission length, and 30-day postoperative complication rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 82 patients, 32 (39%) underwent robotic and 50 (61%) underwent 3-dimensional laparoscopic colorectal surgery. Robotic ultralow and low anterior resection, as well as abdominoperineal resection, resulted in significantly more days at home (23 vs 15 days at home, p = 0.05) and a shorter length of index admission (7 vs 15 days in hospital, p = 0.0003). However, there was no significant difference in major postoperative complications and 30-day readmission rate. No significant differences were found between robotic and 3-dimensional laparoscopic right hemicolectomy or high anterior resection.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Unrandomized study. Patient selection for robotic and 3-dimensional laparoscopic surgery was at the surgeons' discretion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients undergoing robotic ultralow and low anterior resection, as well as abdominoperineal resection, spent more days at home 30 days after index surgery due to a reduction in the length of the index hospital admission. Days at home up to 30 days may enhance the informed consent and complement traditional end points in future clinical trials. See Abstract Video .</AbstractText><AbstractText Label="DAS EN CASA HASTA DAS DESPUS DE LA CIRUGA COLORRECTAL ROBTICA FRENTE A LA LAPAROSCPICA" NlmCategory="UNASSIGNED">ANTECEDENTES:&#xab;D&#xed;as en el hogar hasta 30 d&#xed;as&#xbb; es una nueva m&#xe9;trica de resultados centrada en el paciente que mide el n&#xfa;mero de d&#xed;as que los pacientes pasan en su hogar 30 d&#xed;as despu&#xe9;s de la cirug&#xed;a. Abarca la estancia hospitalaria desde el ingreso inicial, los traslados entre hospitales y los traslados a unidades de cuidados intermedios, as&#xed; como los reingresos en diferentes hospitales.OBJETIVO:Comparaci&#xf3;n de los d&#xed;as en casa hasta 30 d&#xed;as y las m&#xe9;tricas de resultados establecidas tras la cirug&#xed;a rob&#xf3;tica frente a la cirug&#xed;a laparosc&#xf3;pica tridimensional.DISE&#xd1;O:Estudio prospectivo de cohortes de pacientes consecutivos.ENTORNO:Hospital Universitario de Townsville y Hospital Privado Mater, Townsville, Queensland, Australia.PACIENTES:Pacientes adultos sometidos a cirug&#xed;a colorrectal rob&#xf3;tica y laparosc&#xf3;pica tridimensional.PRINCIPALES MEDIDAS DE RESULTADO:D&#xed;as en el domicilio hasta 30 d&#xed;as, tasa de reingresos a los 30 d&#xed;as, duraci&#xf3;n de la admisi&#xf3;n inicial y tasas de complicaciones postoperatorias a los 30 d&#xed;as.RESULTADOS:De los 82 pacientes, 32 (39 %) se sometieron a cirug&#xed;a rob&#xf3;tica y 50 (61 %) a cirug&#xed;a colorrectal laparosc&#xf3;pica tridimensional. La resecci&#xf3;n anterior rob&#xf3;tica ultrabaja y baja, as&#xed; como la resecci&#xf3;n abdominoperineal, dieron lugar a un n&#xfa;mero significativamente mayor de d&#xed;as en el domicilio (23 frente a 15 d&#xed;as en el domicilio, p = 0,05) y a una menor duraci&#xf3;n de la hospitalizaci&#xf3;n inicial (7 frente a 15 d&#xed;as en el hospital, p = 0,0003). Sin embargo, no se observaron diferencias significativas en las complicaciones postoperatorias graves ni en la tasa de reingresos a los 30 d&#xed;as. No se encontraron diferencias significativas entre la hemicolectom&#xed;a derecha rob&#xf3;tica y laparosc&#xf3;pica tridimensional, as&#xed; como la resecci&#xf3;n anterior alta.LIMITACIONES:Estudio no aleatorizado. La selecci&#xf3;n de los pacientes para la cirug&#xed;a rob&#xf3;tica y laparosc&#xf3;pica tridimensional se realiz&#xf3; a criterio de los cirujanos.CONCLUSI&#xd3;N:Los pacientes sometidos a resecci&#xf3;n anterior rob&#xf3;tica ultrabaja y baja, as&#xed; como a resecci&#xf3;n abdominoperineal, pasaron m&#xe1;s d&#xed;as en casa 30 d&#xed;as despu&#xe9;s de la cirug&#xed;a &#xed;ndice debido a la reducci&#xf3;n de la duraci&#xf3;n de la hospitalizaci&#xf3;n &#xed;ndice. Los d&#xed;as en casa hasta 30 d&#xed;as pueden mejorar el consentimiento informado y complementar los criterios de valoraci&#xf3;n tradicionales en futuros ensayos cl&#xed;nicos. (AI-generated translation ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wickramasinghe</LastName><ForeName>Shehan S</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0003-4735-2129</Identifier><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Townsville University Hospital, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Kerenaftali</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Returned and Services League of Australia, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pornkul</LastName><ForeName>Panuwat</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Townsville University Hospital, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mushaya</LastName><ForeName>Chrispen D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Townsville University Hospital, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakata</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Department of Surgery, Townsville University Hospital, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="Y">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011793" MajorTopicYN="N" Type="Geographic">Queensland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colorectal surgery</Keyword><Keyword MajorTopicYN="N">Days at home up to 30 days</Keyword><Keyword MajorTopicYN="N">Days to home</Keyword><Keyword MajorTopicYN="N">Robotic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>15</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40623210</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003861</ArticleId><ArticleId IdType="pii">00003453-990000000-00993</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Erozkan K, Gorgun E. Robotic colorectal surgery and future directions. Am J Surg. 2024;230:91&#x2013;98.</Citation></Reference><Reference><Citation>Yeung TM, Larkins KM, Satish KW, Alexander GH. The rise of robotic colorectal surgery: better for patients and better for surgeons. J Robot Surg. 2024;18:69.</Citation></Reference><Reference><Citation>Sakata S, Grove PM, Stevenson AR. Effect of 3-dimensional vision on surgeons using the da Vinci robot for laparoscopy: more than meets the eye. JAMA Surg. 2016;151:793&#x2013;794.</Citation></Reference><Reference><Citation>Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318:1569&#x2013;1580.</Citation></Reference><Reference><Citation>Feng Q, Yuan W, Li T, et al.; REAL Study Group. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7:991&#x2013;1004.</Citation></Reference><Reference><Citation>Angehrn FVS, Schneider R, Wilhelm A, et al. Robotic versus laparoscopic low anterior resection following neoadjuvant chemoradiation therapy for stage II-III locally advanced rectal cancer: a single-centre cohort study. J Robot Surg. 2022;16:1133&#x2013;1141.</Citation></Reference><Reference><Citation>Hettiarachchi TS, Askari A, Rudge E, et al. Comparison of robotic vs laparoscopic left-sided colorectal cancer resections. J Robot Surg. 2023;17:205&#x2013;213.</Citation></Reference><Reference><Citation>Lim S, Nagai Y, Nozawa H, et al. Surgical outcomes of robotic, laparoscopic, and open low anterior resection after preoperative chemoradiotherapy for patients with advanced lower rectal cancer. Surg Today. 2023;53:109&#x2013;115.</Citation></Reference><Reference><Citation>Bell M, Eriksson LI, Svensson T, et al. Days at home after surgery: an integrated and efficient outcome measure for clinical trials and quality assurance. EClin Med. 2019;11:18&#x2013;26.</Citation></Reference><Reference><Citation>Myles PS, Shulman MA, Heritier S, et al. Validation of days at home as an outcome measure after surgery: a prospective cohort study in Australia. BMJ Open. 2017;7:e015828.</Citation></Reference><Reference><Citation>Jerath A, Austin PC, Wijeysundera DN. Days alive and out of hospital: validation of a patient-centered outcome for perioperative medicine. Anesthesiology. 2019;131:84&#x2013;93.</Citation></Reference><Reference><Citation>Flynn J, Larach JT, Kong JCH, et al. Operative and oncological outcomes after robotic rectal resection compared with laparoscopy: a systematic review and meta-analysis. ANZ J Surg. 2023;93:510&#x2013;521.</Citation></Reference><Reference><Citation>Khan MH, Tahir A, Hussain A, Monis A, Zahid S, Fatima M. Outcomes of robotic versus laparoscopic-assisted surgery in patients with rectal cancer: a systematic review and meta-analysis. Langenbecks Arch Surg. 2024;409:269.</Citation></Reference><Reference><Citation>Feng Q, Tang W, Zhang Z, et al. Robotic versus laparoscopic abdominoperineal resections for low rectal cancer: a single-center randomized controlled trial. J Surg Oncol. 2022;126:1481&#x2013;1493.</Citation></Reference><Reference><Citation>Sakata S, Watson MO, Grove PM, Stevenson AR. The conflicting evidence of three-dimensional displays in laparoscopy: a review of systems old and new. Ann Surg. 2016;263:234&#x2013;239.</Citation></Reference><Reference><Citation>Sakata S, Grove PM, Hill A, Watson MO, Stevenson ARL. Impact of simulated three-dimensional perception on precision of depth judgements, technical performance and perceived workload in laparoscopy. Br J Surg. 2017;104:1097&#x2013;1106.</Citation></Reference><Reference><Citation>Bastawrous AL, Shih I-F, Li Y, Cleary RK. Minimally invasive sigmoidectomy for diverticular disease decreases inpatient opioid use: results of a propensity score-matched study. Am J Surg. 2020;220:421&#x2013;427.</Citation></Reference><Reference><Citation>Bastawrous AL, Brockhaus KK, Chang MI, et al. A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use. Surg Endosc. 2022;36:701&#x2013;710.</Citation></Reference><Reference><Citation>Berger Y, Khajoueinejad N, Imtiaz S, et al. Robotic colorectal resections are associated with less postoperative pain, decreased opioid use, and earlier return to work as compared to the laparoscopic approach. J Robot Surg. 2024;18:336.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40492557</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Cost-Effectiveness of Rubber Band Ligation Versus Hemorrhoidectomy for the Treatment of Grade III Hemorrhoids: Analysis Using Evidence From the HOLLAND Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>1100</StartPage><EndPage>1111</EndPage><MedlinePgn>1100-1111</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003832</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hemorrhoids significantly impact quality of life and health care costs. Although rubber band ligation and hemorrhoidectomy are common treatments for grade III hemorrhoids, comparative cost-effectiveness data are limited.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the cost-effectiveness and cost-utility of rubber band ligation compared to hemorrhoidectomy from a societal perspective within the context of the HOLLAND trial.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cost-effectiveness and cost-utility analyses using data from a multicenter, randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Ten Dutch hospitals participating in the HOLLAND trial.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Adults with symptomatic grade III hemorrhoids randomly assigned to receive rubber band ligation or hemorrhoidectomy treatment.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Rubber band ligation (up to 2 sessions) or excisional hemorrhoidectomy.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Cost per quality-adjusted life year gained and cost per recurrence avoided over 24 months from a societal perspective.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seventy-nine patients were analyzed (33 for hemorrhoidectomy and 46 for rubber band ligation). Hemorrhoidectomy resulted in better clinical outcomes with a quality-adjusted life year difference of 0.08 (95% CI, 0.04-0.13) and a recurrence difference of 33.5% (95% CI, 15.3%-51.7%). Hospital costs were higher for hemorrhoidectomy (&#x20ac;1364; 95% CI, 895-1834; p &lt; 0.001), as were societal costs (&#x20ac;1984; 95% CI, -132 to 4101; p = 0.066). The incremental cost-utility ratio for hemorrhoidectomy was &#x20ac;24,042 per quality-adjusted life year gained, and the incremental cost-effectiveness ratio was &#x20ac;5918 per recurrence avoided. The probability of hemorrhoidectomy being cost-effective was 45.5% at &#x20ac;20,000 per quality-adjusted life year and 83.9% at &#x20ac;50,000 per quality-adjusted life year. For recurrence avoidance, probabilities were 98.3% and 99.8%, respectively.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The small sample size may limit generalizability and the ability to detect rare but costly complications. Procedural costs were based on average hospital prices, which is a pragmatic approach but is less detailed than bottom-up costing.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with grade III hemorrhoids, hemorrhoidectomy provides better long-term clinical outcomes, including higher quality of life and lower recurrence rates compared to rubber band ligation. However, its cost-effectiveness varies depending on societal willingness-to-pay thresholds. Caution is warranted before discarding it as a first-line treatment solely based on health care costs or limited operating room availability. See Video Abstract .</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT04621695.</AbstractText><AbstractText Label="COSTOEFECTIVIDAD DE LA LIGADURA CON BANDA ELSTICA VERSUS HEMORROIDECTOMA PARA EL TRATAMIENTO DE HEMORROIDES DE GRADO III ANLISIS UTILIZANDO EVIDENCIA DEL ENSAYO HOLLAND CONTROLADO ALEATORIZADO" NlmCategory="UNASSIGNED">ANTECEDENTES:Las hemorroides afectan significativamente la calidad de vida y los costos de atenci&#xf3;n m&#xe9;dica. Si bien la ligadura con banda el&#xe1;stica y la hemorroidectom&#xed;a son tratamientos comunes para las hemorroides de grado III, los datos comparativos de costo-efectividad son limitados.OBJETIVO:Evaluar el costo-efectividad y el costo-utilidad de la ligadura con banda el&#xe1;stica en comparaci&#xf3;n con la hemorroidectom&#xed;a desde una perspectiva social en el contexto del ensayo HOLLAND.DISE&#xd1;O:An&#xe1;lisis de costo-efectividad y costo-utilidad utilizando datos de un ensayo controlado aleatorizado multic&#xe9;ntrico.ESTABLECIMIENTO:Diez hospitales holandeses participantes en el ensayo HOLLAND.PACIENTES:Adultos con hemorroides sintom&#xe1;ticas de grado III aleatorizados a ligadura con banda el&#xe1;stica o hemorroidectom&#xed;a.INTERVENCIONES:Ligadura con banda el&#xe1;stica (hasta dos sesiones) o hemorroidectom&#xed;a escisional.PRINCIPALES MEDIDAS DE VALORACI&#xd3;N:Costo por a&#xf1;o de vida ajustado a calidad (AVAC) ganado y costo por recurrencia evitada durante 24 meses desde una perspectiva social.RESULTADOS:Se analizaron setenta y nueve pacientes (33 hemorroidectom&#xed;a, 46 ligadura con banda el&#xe1;stica). La hemorroidectom&#xed;a present&#xf3; mejores resultados cl&#xed;nicos, con una diferencia de AVAC de 0,08 (IC del 95 %, 0,04-0,13) y una diferencia de recurrencia del 33,5 % (IC del 95 %, 15,3 %-51,7 %). Los costes hospitalarios fueron mayores para la hemorroidectom&#xed;a (1364 &#x20ac;; IC del 95 %, 895-1834; p &lt; 0,001), al igual que los costes sociales (1984 &#x20ac;; IC del 95 %, -132-4101; p = 0,066). La raz&#xf3;n costo-utilidad incremental para la hemorroidectom&#xed;a fue de 24.042 &#x20ac; por AVAC ganado, y la raz&#xf3;n costo-efectividad incremental fue de 5.918 &#x20ac; por recurrencia evitada. La probabilidad de que la hemorroidectom&#xed;a sea costo-efectiva fue del 45,5% con 20.000 &#x20ac;/AVAC y del 83,9% con 50.000 &#x20ac;/AVAC. Para la prevenci&#xf3;n de la recurrencia, las probabilidades fueron del 98,3% y del 99,8%, respectivamente.LIMITACIONES:El peque&#xf1;o tama&#xf1;o de la muestra puede limitar la generalizaci&#xf3;n y la capacidad de detectar complicaciones poco frecuentes pero costosas. Los costos del procedimiento se basaron en los precios hospitalarios promedio, lo cual constituye un enfoque pragm&#xe1;tico, aunque menos detallado que el c&#xe1;lculo de costos ascendente.CONCLUSIONES:En pacientes con hemorroides de grado III, la hemorroidectom&#xed;a ofrece mejores resultados cl&#xed;nicos a largo plazo, incluyendo una mayor calidad de vida y menores tasas de recurrencia en comparaci&#xf3;n con la ligadura con banda el&#xe1;stica. Sin embargo, su costo-efectividad var&#xed;a en funci&#xf3;n de los umbrales de disposici&#xf3;n a pagar de la sociedad. Se recomienda precauci&#xf3;n antes de descartarla como tratamiento de primera l&#xed;nea bas&#xe1;ndose &#xfa;nicamente en los costos sanitarios o la disponibilidad limitada de quir&#xf3;fanos. (Traducci&#xf3;n--Ingrid Melo ).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Oostendorp</LastName><ForeName>Justin Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Proctos Kliniek, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekker</LastName><ForeName>Lisette</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8092-7196</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Proctos Kliniek, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Dieren</LastName><ForeName>Susan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3084-0495</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldkamp</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0002-2553-6875</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Proctos Kliniek, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bemelman</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0002-1037-9945</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han-Geurts</LastName><ForeName>Ingrid J M</ForeName><Initials>IJM</Initials><Identifier Source="ORCID">0000-0001-5058-0574</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Proctos Kliniek, Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HOLLAND study group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04621695</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="Y">Hemorrhoids</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008026" MajorTopicYN="N">Ligation</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061865" MajorTopicYN="Y">Hemorrhoidectomy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cost</Keyword><Keyword MajorTopicYN="N">Cost-effectiveness</Keyword><Keyword MajorTopicYN="N">Goligher grade III</Keyword><Keyword MajorTopicYN="N">Hemorrhoidectomy</Keyword><Keyword MajorTopicYN="N">Hemorrhoids</Keyword><Keyword MajorTopicYN="N">Rubber band ligation</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Han-Geurts</LastName><ForeName>I J M</ForeName><Initials>IJM</Initials><AffiliationInfo><Affiliation>surgeon at the Proctos Kliniek.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Bemelman</LastName><ForeName>W A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>surgeon at the Amsterdam UMC.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>van Oostendorp</LastName><ForeName>J Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>surgeon at Groene Hart Ziekenhuis.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Breukink</LastName><ForeName>S O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>surgeon at Maastricht UMC.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>de Castro</LastName><ForeName>S M M</ForeName><Initials>SMM</Initials><AffiliationInfo><Affiliation>surgeon at OLVG.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Meij</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>surgeon at Central Military Hospital Utrecht.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>van Ruler</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>surgeon at Ijsselland Ziekenhuis.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Schiphorst</LastName><ForeName>A H W</ForeName><Initials>AHW</Initials><AffiliationInfo><Affiliation>surgeon at Diakonessenhuis.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Schouten</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>surgeon at Flevoziekenhuis.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Veldkamp</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>surgeon at Proctos Kliniek.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>van Dieren</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>epidemiologist/statistician at the Department of Surgery Amsterdam UMC.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>13</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>7</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40492557</ArticleId><ArticleId IdType="pmc">PMC12345815</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003832</ArticleId><ArticleId IdType="pii">00003453-990000000-00968</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riss S, Weiser FA, Schwameis K, et al. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012;27:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21932016</ArticleId></ArticleIdList></Reference><Reference><Citation>Riss S, Weiser FA, Riss T, Schwameis K, Mittlb&#xf6;ck M, Stift A. Haemorrhoids and quality of life. Colorectal Dis. 2011;13:e48&#x2013;e52.</Citation><ArticleIdList><ArticleId IdType="pubmed">20977590</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JY, Peery AF, Lund JL, Pate V, Sandler RS. Burden and cost of outpatient hemorrhoids in the United States employer-insured population, 2014. Am J Gastroenterol. 2019;114:798&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6502684</ArticleId><ArticleId IdType="pubmed">30741736</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo G, Martellucci J, Sturiale A, et al. Consensus statement of the Italian Society of Colorectal Surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Coloproctol. 2020;24:145&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7005095</ArticleId><ArticleId IdType="pubmed">31993837</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tol RR, Kleijnen J, Watson AJM, et al. European Society of ColoProctology: guideline for haemorrhoidal disease. Colorectal Dis. 2020;22:650&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">32067353</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of hemorrhoids. Dis Colon Rectum. 2018;61:284&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">29420423</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher JC, Dutchie HL, Nixon HH. Surgery of the Anus, Rectum and Colon. 3rd ed. London: Bailli&#xe8;re Tindall; 1975.</Citation></Reference><Reference><Citation>van Tol RR, Bruijnen MPA, Melenhorst J, van Kuijk SMJ, Stassen LPS, Breukink SO. A national evaluation of the management practices of hemorrhoidal disease in the Netherlands. Int J Colorectal Dis. 2018;33:577&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899108</ArticleId><ArticleId IdType="pubmed">29546558</ArticleId></ArticleIdList></Reference><Reference><Citation>Altomare DF, Picciariello A, Pecorella G, et al. ; Italian Haemorrhoid Survey Group. Surgical management of haemorrhoids: an Italian survey of over 32 000 patients over 17 years. Colorectal Dis. 2018;20:1117&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">30004171</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanmugam V, Hakeem A, Campbell KL, et al. Rubber band ligation versus excisional haemorrhoidectomy for haemorrhoids. Cochrane Database Syst Rev. 2005;2005:CD005034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8860341</ArticleId><ArticleId IdType="pubmed">16034963</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker L, Han-Geurts IJM, R&#xf8;rvik HD, van Dieren S, Bemelman WA. Rubber band ligation versus haemorrhoidectomy for the treatment of grade II-III haemorrhoids: a systematic review and meta-analysis of randomised controlled trials. Tech Coloproctol. 2021;25:663&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8124052</ArticleId><ArticleId IdType="pubmed">33683503</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown SR, Tiernan JP, Watson AJM, et al. ; HubBLe Study team. Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. Lancet. 2016;388:356&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956910</ArticleId><ArticleId IdType="pubmed">27236344</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker L, Bak MTJ, Bemelman WA, Felt-Bersma RJF, Han-Geurts IJM. Hemorrhoidectomy versus rubber band ligation in grade III hemorrhoidal disease: a large retrospective cohort study with long-term follow-up. Ann Coloproctol. 2022;38:146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021858</ArticleId><ArticleId IdType="pubmed">34314581</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson AJ, Hudson J, Wood J, et al. ; eTHoS study group. Comparison of stapled haemorrhoidopexy with traditional excisional surgery for haemorrhoidal disease (eTHoS): a pragmatic, multicentre, randomised controlled trial. Lancet. 2016;388:2375&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5269572</ArticleId><ArticleId IdType="pubmed">27726951</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshreef A, Wailoo AJ, Brown SR, et al. Cost-effectiveness of haemorrhoidal artery ligation versus rubber band ligation for the treatment of grade II-III haemorrhoids: analysis using evidence from the HubBLe trial. PharmacoEcon Open. 2017;1:175&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5691841</ArticleId><ArticleId IdType="pubmed">29441497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehur PA, Didn&#xe9;e AS, Faucheron JL, et al. ; LigaLongo Study Group. Cost-effectiveness of new surgical treatments for hemorrhoidal disease: a multicentre randomized controlled trial comparing transanal Doppler-guided hemorrhoidal artery ligation with mucopexy and circular stapled hemorrhoidopexy. Ann Surg. 2016;264:710&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">27741005</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie L, de Verteuil R, Cook J, et al. Economic evaluation of the treatment of grade II haemorrhoids: a comparison of stapled haemorrhoidopexy and rubber band ligation. Colorectal Dis. 2010;12:587&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">19508532</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin OP, Wright ME, Thorson AG, Ternent CA. Hemorrhoid banding: a cost-effectiveness analysis. Dis Colon Rectum. 2019;62:1085&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">31318773</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oostendorp JY, Dekker L, van Dieren S, Veldkamp R, Bemelman WA, Han-Geurts IJM; HollAND Study Group. Comparison of rubber band ligation and hemorrhoidectomy in patients with symptomatic hemorrhoids grade III (HOLLAND): a multicenter, open-label, randomized controlled, non-inferiority trial. Dis Colon Rectum. 2025;68:572&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11999089</ArticleId><ArticleId IdType="pubmed">39952268</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker L, Han-Geurts IJM, van Dieren S, Bemelman WA. HOLLAND trial: comparison of rubber band ligation and haemorrhoidectomy in patients with symptomatic haemorrhoids grade III: study protocol for a multicentre, randomised controlled trial and cost&#x2013;utility analysis. BMJ Open. 2021;11:e046836.</Citation></Reference><Reference><Citation>Husereau D, Drummond M, Augustovski F, et al. ; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35031096</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute for Medical Technology Assessment
iMTA Medical Consumption Questionnaire.
https://www.imta.nl/questionnaires/imcq/. Accessed February 10, 2025.</Citation></Reference><Reference><Citation>Bouwmans C, Krol M, Severens H, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L. The iMTA Productivity Cost Questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18:753&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">26409601</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Care Institute. Guideline for economic evaluations in healthcare (2024 version).
https://english.zorginstituutnederland.nl/publications/reports/2024/01/16/guideline-for-economic-evaluations-in-healthcare. Accessed February 10, 2025.</Citation></Reference><Reference><Citation>National Health Care Institute. Farmacotherapeutisch Kompas.
https://www.farmacotherapeutischkompas.nl/. Accessed February 10, 2025.</Citation></Reference><Reference><Citation>StatLine. Year mutation consumer price index [in Dutch].
https://opendata.cbs.nl/statline/#/CBS/nl/dataset/70936NED/table?fromstatweb. Accessed February 10, 2025.</Citation></Reference><Reference><Citation>van Reenen M, Janssen B, Stolk E, et al. EQ-5D-5L user guide. https://euroqol.org/wp-content/uploads/2025/01/EQ-5D-5LUserguide-23-07.pdf. Accessed February 10, 2025.</Citation></Reference><Reference><Citation>Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19:343&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">27325326</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand J, van Buuren S, le Cessie S, van den Hout W. Combining multiple imputation and bootstrap in the analysis of cost-effectiveness trial data. Stat Med. 2019;38:210&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585698</ArticleId><ArticleId IdType="pubmed">30207407</ArticleId></ArticleIdList></Reference><Reference><Citation>Federatie Medisch Specialisten. Proctologie.
https://richtlijnendatabase.nl/richtlijn/proctologie/behandelalgoritme_symptomatische_hemorroiden.html. Accessed February 10, 2025.</Citation></Reference><Reference><Citation>Iacobucci G. NHS proposes to stop funding 17 &#x201c;unnecessary&#x201d; procedures. BMJ. 2018;362:k2903.</Citation><ArticleIdList><ArticleId IdType="pubmed">29967052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38830268</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Effect of Sublay Preventive Mesh for Terminal Colostomy on Symptoms and Quality of Life in Patients With Parastomal Hernia: A Post Hoc Analysis of the GRECCAR 7 Cohort.</ArticleTitle><Pagination><StartPage>1210</StartPage><EndPage>1216</EndPage><MedlinePgn>1210-1216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003257</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent randomized clinical trials and meta-analyses confirm that the use of a prophylactic mesh does not significantly reduce the parastomal hernia rate. Data about the benefits of these meshes concerning the symptoms of parastomal hernia are lacking in the existing literature.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to perform a post hoc analysis of the patients presenting parastomal hernia from the GRECCAR 7 (Groupe de recherche sur la chirurgie du cancer du rectum) randomized clinical trials cohort on whether the presence or the absence of the mesh influenced the symptoms, the quality of life, and complications of patients with parastomal hernias.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We studied the parastomal hernia-related symptoms among the 2 groups of the GRECCAR 7 randomized clinical trial, with or without prophylactic mesh at the time of the index surgery.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Data were retrospectively extracted and analyzed from the GRECCAR 7 database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients diagnosed with a parastomal hernia during the 2 years of the GRECCAR 7 study.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Several prospectively collected data about the symptoms were studied among this population. We also studied the average interval between parastomal hernia repair surgery and both index surgery and diagnosis of parastomal hernia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 199 patients included in the GRECCAR study, 36 patients (35.6%) in the nonmesh group and 33 patients (33.7%) in the mesh group were diagnosed with clinical and/or radiological parastomal hernia at 2-year follow-up, without a statistically significant difference ( p = 0.89). None of the studied symptoms showed any statistically significant difference between the groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study relies on a relatively small number of patients, and although data were prospectively collected, we lacked some details about the categorization of parastomal hernias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We believe that the use of a prosthetic mesh in a sublay position to prevent parastomal hernia in terminal end colostomy patients should no longer be recommended. See Video Abstract .</AbstractText><AbstractText Label="EFECTO DE LA MALLA PREVENTIVA RETROMUSCULAR PARA COLOSTOMA TERMINAL CON RESPECTO A LOS SNTOMAS Y LA CALIDAD DE VIDA EN PACIENTES CON HERNIA PARAESTOMAL UN ANLISIS POSTHOC DE LA COHORTE GRECCAR" NlmCategory="UNASSIGNED">ANTECEDENTES:Los recientes metaan&#xe1;lisis y ensayos cl&#xed;nicos aleatorizados confirman que el uso de una malla profil&#xe1;ctica no reduce significativamente la tasa de hernia paraestomal. En la literatura existente faltan datos sobre los beneficios de estas mallas en relaci&#xf3;n con los s&#xed;ntomas de la hernia paraestomal.OBJETIVO:El objetivo de este estudio fue realizar un an&#xe1;lisis post-hoc de los pacientes que presentaron hernia paraestomal de la cohorte de 7 ensayos cl&#xed;nicos aleatorizados GRECCAR sobre si la presencia o ausencia de la malla influy&#xf3; en los s&#xed;ntomas, la calidad de vida y las complicaciones de los pacientes con hernias paraestomales.DISE&#xd1;O:Estudiamos los s&#xed;ntomas relacionados con la hernia paraestomal entre los dos grupos del ensayo cl&#xed;nico aleatorizado GRECCAR 7, con o sin malla profil&#xe1;ctica en el momento de la cirug&#xed;a &#xed;ndice.AJUSTES:Los datos fueron extra&#xed;dos y analizados de manera retrospectiva de la base de datos GRECCAR 7.PACIENTES:Pacientes diagnosticados con hernia paraestomal durante los dos a&#xf1;os del estudio GRECCAR 7.PRINCIPALES MEDIDAS DE RESULTADO:Se estudiaron varios datos recopilados de manera prospectiva sobre los s&#xed;ntomas en esta poblaci&#xf3;n. Tambi&#xe9;n estudiamos el intervalo promedio entre la cirug&#xed;a reparadora de la hernia paraestomal as&#xed; como tambi&#xe9;n la cirug&#xed;a &#xed;ndice como el diagn&#xf3;stico de la hernia paraestomal.RESULTADOS:De entre los 199 pacientes incluidos en el estudio GRECCAR, 36 pacientes (35,6%) fueron diagnosticados con hernia paraestomal de manera cl&#xed;nica y/o radiol&#xf3;gica en el grupo sin malla a los 2 a&#xf1;os de seguimiento y 33 (33,7%) en el grupo con malla, sin diferencia estad&#xed;sticamente significativa ( p = 0,89). Ninguno de los s&#xed;ntomas estudiados mostr&#xf3; diferencias estad&#xed;sticamente significativas entre los grupos.LIMITACIONES:Este estudio se basa en un n&#xfa;mero relativamente peque&#xf1;o de pacientes y, aunque los datos fueron recopilados de forma prospectiva, nos faltaron algunos detalles sobre la categorizaci&#xf3;n de las hernias paraestomales.CONCLUSIONES:Creemos que ya no se debe recomendar el uso de una malla prot&#xe9;sica en posici&#xf3;n retromuscular para prevenir la hernia paraestomal en pacientes con colostom&#xed;a terminal. (Traducci&#xf3;n-Dr. Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Martin M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theuil</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demattei</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudhomme</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GRECCAR Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013526" MajorTopicYN="Y">Surgical Mesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003125" MajorTopicYN="Y">Colostomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069290" MajorTopicYN="N">Incisional Hernia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054047" MajorTopicYN="N">Surgical Stomas</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006555" MajorTopicYN="N">Hernia, Ventral</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38830268</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003257</ArticleId><ArticleId IdType="pii">00003453-202409000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carne P, Robertson G, Frizelle F. Parastomal hernia. Br J Surg. 2003;90:1306&#x2013;1307.</Citation></Reference><Reference><Citation>National Bowel Cancer Audit. Annual report 2021. An audit of the care received by people with bowel cancer in England and Wales. https://www.nboca.org.uk/content/uploads/2022/02/NBOCA-2021-AR-Final.pdf . Accessed August 31, 2023.</Citation></Reference><Reference><Citation>Glasgow SC, Dharmarajan S. Parastomal hernia: avoidance and treatment in the 21st century. Clin Colon Rectal Surg. 2016;29:277&#x2013;284.</Citation></Reference><Reference><Citation>Londono-Schimmer E, Leong A, Phillips R. Life table analysis of stomal complications following colostomy. Dis Colon Rectum. 1994;37:916&#x2013;920.</Citation></Reference><Reference><Citation>Ripoche J, Basurko C, Fabbro-Perray P, Prudhomme M. Parastomal hernia. A study of the French federation of ostomy patients. J Visc Surg. 2011;148:e435&#x2013;e441.</Citation></Reference><Reference><Citation>Antoniou S, Agresta F, Alamino JG, et al. European Hernia Society guidelines on prevention and treatment of parastomal hernias. Hernia. 2018;22:183&#x2013;198.</Citation></Reference><Reference><Citation>ACPGBI Parastomal Hernia Group. Prevention and treatment of parastomal hernia: a position statement on behalf of the Association of Coloproctology of Great Britain and Ireland. Colorectal Dis. 2018;20(suppl 2):5&#x2013;19.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. Interventional procedures guidance [IPG654]. https://www.nice.org.uk/guidance/ipg654/resources/reinforcement-of-a-permanent-stoma-with-a-synthetic-or-biological-mesh-to-prevent-a-parastomal-hernia-pdf-1899874164041413 . Accessed August 31, 2023.</Citation></Reference><Reference><Citation>Aslam M, Rubio-Perez I, Smart N, Singh B; Committee ESoCE. A survey on practices for parastomal hernia prevention and repair among ESCP surgeons. Hernia. 2019;23:825&#x2013;828.</Citation></Reference><Reference><Citation>Prudhomme M, Rullier E, Lakkis Z, et al.; GRECCAR research group. End colostomy with or without mesh to prevent a parastomal hernia (GRECCAR 7): a prospective, randomized, double blinded, multicentre trial. Ann Surg. 2021;274:928&#x2013;934.</Citation></Reference><Reference><Citation>Odensten C, Strig&#xe5;rd K, Ruteg&#xe5;rd J, et al. Use of prophylactic mesh when creating a colostomy does not prevent parastomal hernia: a randomized controlled trial&#x2014;STOMAMESH. Ann Surg. 2019;269:427&#x2013;431.</Citation></Reference><Reference><Citation>Prudhomme M, Fabbro-Peray P, Rullier E, Occean BV, Bertrand MM. Meta-analysis and systematic review of the use of a prosthetic mesh for prevention of parastomal hernia. Ann Surg. 2021;274:20&#x2013;28.</Citation></Reference><Reference><Citation>Serra-Aracil X, Bombardo-Junca J, Moreno-Matias J, et al. Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia. Ann Surg. 2009;249:583&#x2013;587.</Citation></Reference><Reference><Citation>Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K. Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial. Colorectal Dis. 2015;17:O191&#x2013;O197.</Citation></Reference><Reference><Citation>L&#xf3;pez-Cano M, Lozoya-Trujillo R, Quiroga S, et al. Use of a prosthetic mesh to prevent parastomal hernia during laparoscopic abdominoperineal resection: a randomized controlled trial. Hernia. 2012;16:661&#x2013;667.</Citation></Reference><Reference><Citation>L&#xf3;pez-Cano M, Serra-Aracils X, Mora L, et al. Preventing parastomal hernia using a modified Sugarbaker technique with composite mesh during laparoscopic abdominoperineal resection. Ann Surg. 2016;264:923&#x2013;928.</Citation></Reference><Reference><Citation>J&#xe4;nes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. Br J Surg. 2004;91:280&#x2013;282.</Citation></Reference><Reference><Citation>Fleshman JW, Beck DE, Hyman N, Wexner SD, Bauer J, George V; PRISM Study Group. A prospective, multicenter, randomized, controlled study of non-cross-linked porcine acellular dermal matrix fascial sublay for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. Dis Colon Rectum. 2014;57:623&#x2013;631.</Citation></Reference><Reference><Citation>Vierimaa M, Klintrup K, Biancari F, et al. Prospective, randomized study on the use of a prosthetic mesh for prevention of parastomal hernia of permanent colostomy. Dis Colon Rectum. 2015;58:943&#x2013;949.</Citation></Reference><Reference><Citation>M&#xe4;k&#xe4;r&#xe4;inen-Uhlb&#xe4;ck EJ, Klintrup KH, Vierimaa MT, et al. Prospective, randomized study on the use of prosthetic mesh to prevent a parastomal hernia in a permanent colostomy: results of a long-term follow-up. Dis Colon Rectum. 2020;63:678&#x2013;684.</Citation></Reference><Reference><Citation>Rajaretnam N, Smart NJ. To mesh or not to mesh&#x2014;the known unknowns of preventing parastomal hernias. Br J Surg. 2022;109:1&#x2013;2.</Citation></Reference><Reference><Citation>Prudhomme M, Alline M, Chauvat J, Fabbro-Perray P, Ripoche J, Bertrand MM; French Research Group of Rectal Cancer Surgery (GRECCAR). Primary prevention of peristomial hernias via parietal prostheses: a randomized, multicentric study (GRECCAR 7 trial). Dig Liver Dis. 2016;48:812&#x2013;816.</Citation></Reference><Reference><Citation>Prieto L, Thorsen H, Juul K. Development and validation of a quality of life questionnaire for patients with colostomy or ileostomy. Health Qual Life Outcomes. 2005;3:1&#x2013;10.</Citation></Reference><Reference><Citation>Marinez AC, Bock D, Carlsson E, et al. Stoma-related complications: a report from the Stoma-Const randomized controlled trial. Colorectal Dis. 2021;23:1091&#x2013;1101.</Citation></Reference><Reference><Citation>Marinez AC, Bock D, Erestam S, et al. Methods of colostomy construction: no effect on parastomal hernia rate: results from stoma-const&#x2014;a randomized controlled trial. Ann Surg. 2021;273:640&#x2013;647.</Citation></Reference><Reference><Citation>N&#xe4;verlo S, Gunnarsson U, Strig&#xe5;rd K, N&#xe4;svall P. Quality of life after end colostomy without mesh and with prophylactic synthetic mesh in sublay position: one-year results of the STOMAMESH trial. Int J Colorectal Dis. 2019;34:1591&#x2013;1599.</Citation></Reference><Reference><Citation>Brandsma H-T, Hansson BM, Aufenacker TJ, et al.; Dutch Prevent Study group. Prophylactic mesh placement during formation of an end-colostomy reduces the rate of parastomal hernia. Ann Surg. 2017;265:663&#x2013;669.</Citation></Reference><Reference><Citation>Conde-Mu&#xed;&#xf1;o R, D&#xed;ez JL, Mart&#xed;nez A, Huertas F, Segura I, Palma P. Preventing parastomal hernias with systematic intraperitoneal specifically designed mesh. BMC Surg. 2017;17:41.</Citation></Reference><Reference><Citation>Luo J, Singh D, Zhang F, et al. Comparison of the extraperitoneal and transperitoneal routes for permanent colostomy: a meta-analysis with RCTs and systematic review. World J Surg Oncol. 2022;20:82.</Citation></Reference><Reference><Citation>M&#xe4;k&#xe4;r&#xe4;inen-Uhlb&#xe4;ck E, Wiik H, K&#xf6;ssi J, Nikberg M, Ohtonen P, Rautio T. Chimney Trial: study protocol for a randomized controlled trial. Trials. 2019;20:652.</Citation></Reference><Reference><Citation>Liu Y, Fu X, Chen H, Yao Q. Surgical strategies for recurrent parastomal hernia after a primary repair with a Dynamesh(&#xae;) IPST mesh. Hernia. 2023;27:617&#x2013;621.</Citation></Reference><Reference><Citation>Chapman SJ, Wood B, Drake TM, Young N, Jayne DG. Systematic review and meta-analysis of prophylactic mesh during primary stoma formation to prevent parastomal hernia. Dis Colon Rectum. 2017;60:107&#x2013;115.</Citation></Reference><Reference><Citation>Hansson BM, Slater NJ, van der Velden AS, et al. Surgical techniques for parastomal hernia repair: a systematic review of the literature. Ann Surg. 2012;255:685&#x2013;695.</Citation></Reference><Reference><Citation>PROPHER Study Collaborating Group. The PROPHER Study: patient reported outcomes after parastomal hernia treatment&#x2014;a prospective international cohort study. Colorectal Dis. 2024;26:554&#x2013;563.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38718322</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">0717-6384</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>Medwave</Title><ISOAbbreviation>Medwave</ISOAbbreviation></Journal><ArticleTitle>Protocol for a systematic mapping review of surgical and pharmacological interventions for the treatment of trigeminal neuralgia.</ArticleTitle><Pagination><StartPage>e2759</StartPage><MedlinePgn>e2759</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5867/medwave.2024.04.2759</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Trigeminal neuralgia is a painful neuropathic disorder characterized by sudden electric shock-like pain that significantly impacts patients' quality of life. Multiple treatment alternatives are available, including medical and surgical options but establishing the optimal course of action can be challenging. To enhance clinical decision-making for trigeminal neuralgia treatment, it is imperative to organize, describe and map the available systematic reviews and randomized trials. This will help identify the best treatment alternatives supported by evidence and acknowledge potential knowledge gaps where future research is needed.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This systematic mapping review aims to provide up-to-date evidence on the different surgical and pharmacological treatment alternatives used for trigeminal neuralgia.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A search will be systematically conducted on the Epistemonikos database to identify potentially eligible systematic reviews. Additionally, a search will be made in PubMed, CENTRAL, and EBSCO to identify randomized controlled trials assessing pharmacological and surgical treatment interventions for trigeminal neuralgia. Two independent reviewers will screen and select the studies. Data on the different treatment alternatives and reported outcomes in the included studies will be extracted using standardized forms. Following extraction, descriptive statistical methods will be used to analyze the data. The final output of this study will include an evidence map that will illustrate the connections between different treatments and their respective outcomes, providing a clear depiction of the evidence landscape.</AbstractText><AbstractText Label="EXPECTED RESULTS" NlmCategory="UNASSIGNED">This study expects to map, describe and assess the methodological quality of the available systematic reviews and trials on pharmacological interventions and neurosurgical procedures for treating trigeminal neuralgia. It will present the results in an evidence map that organizes the available evidence based on their different interventions and outcomes. This evidence map will serve as a visual tool to assist healthcare professionals and patients to understand evidence-based treatment options and their implications for managing this medical condition.</AbstractText><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">La neuralgia del trig&#xe9;mino es un trastorno neurop&#xe1;tico doloroso caracterizado por un dolor s&#xfa;bito y agudo, similar a una descarga el&#xe9;ctrica, que impacta significativamente en la calidad de vida. Dada la variedad de tratamientos disponibles, m&#xe9;dicos y quir&#xfa;rgicos, es crucial organizar y mapear la evidencia proveniente de revisiones sistem&#xe1;ticas y ensayos cl&#xed;nicos para orientar las decisiones cl&#xed;nicas. Esto permite identificar tratamientos respaldados por evidencia y se&#xf1;alar &#xe1;reas de investigaci&#xf3;n futura.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">El prop&#xf3;sito de esta revisi&#xf3;n sistem&#xe1;tica de mapeo es proporcionar una visi&#xf3;n actualizada de la evidencia existente en relaci&#xf3;n con las diversas opciones de tratamiento quir&#xfa;rgico y farmacol&#xf3;gico empleadas en el manejo de la neuralgia del trig&#xe9;mino.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Se realizar&#xe1; una b&#xfa;squeda sistem&#xe1;tica en la base de datos Epistemonikos para identificar potenciales revisiones sistem&#xe1;ticas. Adicionalmente, se buscar&#xe1; en PubMed, CENTRAL y EBSCO ensayos cl&#xed;nicos aleatorizados que eval&#xfa;en intervenciones de tratamiento farmacol&#xf3;gico y quir&#xfa;rgico para la neuralgia del trig&#xe9;mino. Dos revisores independientes cribar&#xe1;n y seleccionar&#xe1;n los estudios. Se extraer&#xe1;n datos sobre las diferentes alternativas de tratamiento y los resultados reportados en los estudios incluidos utilizando formularios estandarizados. Tras la extracci&#xf3;n, se utilizar&#xe1;n m&#xe9;todos estad&#xed;sticos descriptivos para analizar los datos. El producto final de este estudio incluir&#xe1; un mapa de evidencia que ilustrar&#xe1; las conexiones entre los diferentes tratamientos y sus respectivos resultados, proporcionando una representaci&#xf3;n clara del panorama de la evidencia.</AbstractText><AbstractText Label="RESULTADOS ESPERADOS" NlmCategory="UNASSIGNED">Los resultados que se extraer&#xe1;n de este mapeo sistem&#xe1;tico incluyen identificar y describir las diferentes alternativas, tanto farmacol&#xf3;gicas como quir&#xfa;rgicas, que existen para el tratamiento de la neuralgia del trig&#xe9;mino. Adem&#xe1;s, se planea presentar un mapa de evidencia que se basar&#xe1; en los ensayos cl&#xed;nicos aleatorizados y revisiones sistem&#xe1;ticas, el cual mostrar&#xe1; la evidencia de manera organizada entre las diferentes intervenciones y sus desenlaces. Este mapa de evidencia servir&#xe1; como una herramienta visual que ayudar&#xe1; a los profesionales de la salud y los pacientes a comprender mejor las opciones de tratamiento respaldadas por la evidencia y sus consecuencias en el manejo de esta condici&#xf3;n m&#xe9;dica.</AbstractText><CopyrightInformation>This work is licensed under a Creative Commons Attribution 4.0 International License.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladevig</LastName><ForeName>Dominga</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0006-9408-6897</Identifier><AffiliationInfo><Affiliation>Escuela de Odontolog&#xed;a, Facultad de Medicina, Cl&#xed;nica Alemana Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veloso</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-0840-788X</Identifier><AffiliationInfo><Affiliation>Escuela de Odontolog&#xed;a, Facultad de Medicina, Cl&#xed;nica Alemana Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila-Oliver</LastName><ForeName>Camila</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5348-6284</Identifier><AffiliationInfo><Affiliation>Escuela de Odontolog&#xed;a, Facultad de Medicina, Cl&#xed;nica Alemana Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Chile</Country><MedlineTA>Medwave</MedlineTA><NlmUniqueID>101581949</NlmUniqueID><ISSNLinking>0717-6384</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014277" MajorTopicYN="Y">Trigeminal Neuralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="Y">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="N">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mapping review</Keyword><Keyword MajorTopicYN="N">Trigeminal nerve</Keyword><Keyword MajorTopicYN="N">Trigeminal neuralgia</Keyword></KeywordList><CoiStatement>No conflicts of interest are declared. No patient and public involvement took place in the development or conduct of this protocol.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>18</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>18</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>8</Day><Hour>16</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38718322</ArticleId><ArticleId IdType="doi">10.5867/medwave.2024.04.2759</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38603800</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn's Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn's Fistula (the PRIME Study).</ArticleTitle><Pagination><StartPage>960</StartPage><EndPage>967</EndPage><MedlinePgn>960-967</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003216</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Perianal fistulas may affect 15% to 50% of patients with Crohn's disease. Treatment is complex, requiring a multidisciplinary approach. Darvadstrocel (allogenic mesenchymal cells obtained from lipoaspirates) was approved in 2018 by the European and Spanish Agencies of Medicines and Medical Products as a treatment for fistulas in Crohn's disease. Recent guidelines from the European Crohn's and Colitis Organisation and Spanish Working Group on Crohn's Disease and Ulcerative Colitis state that darvadstrocel is effective with a favorable safety profile and a strong level of evidence (n&#x2009;=&#x2009;2).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Presenting real-world effectiveness data for darvadstrocel in a Spanish population.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Observational retrospective cohort study with prospective data gathering.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The study was conducted at 14 institutions in Spain.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">From November 2019 to April 2022, all patients (n = 73) treated with darvadstrocel in these institutions were included, fulfilling the following criteria: 1) complex fistula/s in a patient with Crohn's disease; 2) failure of conventional and antitumor necrosis factor treatment; and 3) the absence of collections of &gt;2&#x2009;cm confirmed by pelvic MRI at the time of surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Darvadstrocel treatment.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Clinical response (closure of 50% or more of external openings), complete clinical closure (100% of external openings), and radiological closure (no fluid collection &gt;2&#x2009;cm, edema, or inflammation) evaluated 6 months after treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Clinical response was observed in 63 patients (86.3%), complete clinical closure in 50 patients (68.5%), and radiological closure in 45 patients (69.2%). Combined clinical and radiological response was observed in 41 patients (63.1%). Not all clinically healed patients had radiological closure, and vice versa. No serious adverse events were reported.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective nature of the study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Study results were consistent with those reported in previous clinical trials, real-world efficacy findings from the INSPIRE study (assessing darvadstrocel effectiveness in Europe, Israel, Switzerland, United Kingdom, and Japan), and previously published literature. Darvadstrocel was effective and demonstrated a favorable safety profile when used in normal clinical practice for the treatment of fistulas in Crohn's disease. See Video Abstract .</AbstractText><AbstractText Label="USO DE DARVADSTROCEL TERAPIA CON CLULAS MADRE ALOGNICAS PARA FSTULA EN ENFERMEDAD DE CROHN EN LA PRCTICA CLNICA REAL EL PROYECTO NACIONAL PARA IMPLEMENTAR DE CLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FSTULA DE CROHN PERIANAL EL ESTUDIO PRIME" NlmCategory="UNASSIGNED">ANTECEDENTES:Las f&#xed;stulas perianales pueden afectar entre el 15 y el 50% de los pacientes con enfermedad de Crohn. El tratamiento es complejo y requiere un enfoque multidisciplinario. El darvadstrocel (c&#xe9;lulas mesenquimales alog&#xe9;nicas obtenidas a partir de lipoaspirados) fue aprobado en 2018 por las Agencias Europea y Espa&#xf1;ola de Medicamentos y Productos Sanitarios como tratamiento de las f&#xed;stulas en la EC. Las recientes directrices de la Organizaci&#xf3;n Europea de Crohn y Colitis y del Grupo de Trabajo Espa&#xf1;ol sobre la Enfermedad de Crohn y Colitis Ulcerosa afirman que darvadstrocel es eficaz con un perfil de seguridad favorable y un s&#xf3;lido nivel de evidencia (2).OBJETIVO:Presentar datos de eficacia real de darvadstrocel en poblaci&#xf3;n espa&#xf1;ola.DISE&#xd1;O:Estudio de cohorte retrospectivo observacional con recopilaci&#xf3;n prospectiva de datos.ESCENARIO:14 instituciones.PACIENTES:Desde noviembre de 2019 hasta abril de 2022, se incluyeron todos los pacientes (73) tratados con darvadstrocel en estas instituciones, que cumplieron los siguientes criterios: 1) f&#xed;stula/s compleja/s en un paciente con enfermedad de Crohn; 2) fracaso del tratamiento convencional y anti factor de necrosis tumoral; 3) ausencia de colecciones &gt; 2 cm confirmada por resonancia magn&#xe9;tica p&#xe9;lvica en el momento de la cirug&#xed;a.INTERVENCIONES:Tratamiento con Darvadstrocel.PRINCIPALES MEDIDAS DE RESULTADO:Respuesta cl&#xed;nica (cierre de &#x2265;50% de las aberturas externas), cierre cl&#xed;nico completo (100% de las aberturas externas) y cierre radiol&#xf3;gico (sin acumulaci&#xf3;n de l&#xed;quido &gt;2 cm, sin edema ni inflamaci&#xf3;n) evaluados 6 meses despu&#xe9;s del tratamiento.RESULTADOS:Se observ&#xf3; respuesta cl&#xed;nica en 63 pacientes (86.3%), cierre cl&#xed;nico completo en 50 pacientes (68.5%) y cierre radiol&#xf3;gico en 45 pacientes (69.2%). Se observ&#xf3; respuesta cl&#xed;nica y radiol&#xf3;gica combinada en 41 pacientes (63.1%). No todos los pacientes cl&#xed;nicamente curados tuvieron cierre radiol&#xf3;gico y viceversa. No hubo eventos adversos graves reportados.LIMITACIONES:Estudio retrospectivoCONCLUSIONES:Los resultados del estudio fueron consistentes con los informados en ensayos cl&#xed;nicos anteriores, los hallazgos de eficacia en el mundo real del estudio INSPIRE (que eval&#xfa;a la efectividad de darvadstrocel en Europa, Israel, Suiza, el Reino Unido y Jap&#xf3;n) y la literatura publicada anteriormente. Darvadstrocel fue eficaz y demostr&#xf3; un perfil de seguridad favorable cuando se utiliza en la pr&#xe1;ctica cl&#xed;nica habitual para el tratamiento de f&#xed;stulas en la enfermedad de Crohn. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herreros</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-1136-4518</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Therapy Laboratory, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Zaragoza, Zaragoza, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Multimodal Rehabilitation Group (GERM), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otero-Pi&#xf1;eiro</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;-Gallostra</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Vall Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badiola</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery University Hospital Galdakao-Usansolo, Vizcaya, Pais Vasco, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enr&#xed;quez-Navascues</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Donostia, Biodonostia, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millan</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital la Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barreiro</LastName><ForeName>Erica M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital of Pontevedra, Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Portilla</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery University Hospital Virgen del Rocio, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez Alecha</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital of Navarra, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Olmo</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New Therapy Laboratory, Instituto de Investigaci&#xf3;n Sanitaria Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgery Department, Universidad Autonoma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn&#x2019;s Fistula (the PRIME Study) Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05742100</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Herreros</LastName><ForeName>Maria Dolores</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a-Olmo</LastName><ForeName>Damian</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guadalajara</LastName><ForeName>Hector</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia-Arranz</LastName><ForeName>Mariano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badiola</LastName><ForeName>Izaskun</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fern&#xe1;ndez Miguel</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodr&#xed;guez Lago</LastName><ForeName>Iago</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portugal Porras</LastName><ForeName>Vicente</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golda</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvez</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruiz Cerulla</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreisler</LastName><ForeName>Esther</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otero</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tavares</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pena</LastName><ForeName>Romina</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bravo</LastName><ForeName>Raquel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enr&#xed;quez-Navascues</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Placer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borda</LastName><ForeName>Nerea</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elorza</LastName><ForeName>Garazi</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Millan</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez Chicote</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholewa</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieto</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marti</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espin</LastName><ForeName>Eloi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borruel</LastName><ForeName>Natalia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armario Quiteria Hern&#xe1;ndez</LastName><ForeName>Davis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abrisqueta</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ib&#xe1;&#xf1;ez</LastName><ForeName>Noelia</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoya</LastName><ForeName>Mariano</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Portilla</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>V&#xe1;zquez Monchul</LastName><ForeName>Jorge M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>de la Portilla Le&#xf3;n</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez-Rosado</LastName><ForeName>Juan-Carlos</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres-Arcos</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez-Sanchez</LastName><ForeName>Asuncion</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arg&#xfc;elles-Arias</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barreiro</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez de Los Reyes</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Guillen</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alcaide-Quir&#xf3;s</LastName><ForeName>M Jos&#xe9;</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arroyo</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xf3;pez-Rodr&#xed;guez-Arias</LastName><ForeName>Francisco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suarez Alecha</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oronoz</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>Saioa</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicu&#xf1;a</LastName><ForeName>Miren</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>11</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38603800</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003216</ArticleId><ArticleId IdType="pii">00003453-202407000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg. 1976;63:1&#x2013;12.</Citation></Reference><Reference><Citation>Vigano C, Losco A, Caprioli F, Basilisco G. Incidence and clinical outcomes of intersphincteric abscesses diagnosed by anal ultrasonography in patients with Crohn&#x2019;s disease. Inflamm Bowel Dis. 2011;17:2102&#x2013;2108.</Citation></Reference><Reference><Citation>Limura E, Giordano P. Modern management of anal fistula. World J Gastroenterol. 2015;21:12&#x2013;20.</Citation></Reference><Reference><Citation>Panes J, Rimola J. Perianal fistulizing Crohn&#x2019;s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652&#x2013;664.</Citation></Reference><Reference><Citation>Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol. 1984;73:219&#x2013;224.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Van Assche G, Tagarro I, et al. Prevalence of anal fistulas in Europe: systematic literature reviews and population-based database analysis. Adv Ther. 2019;36:3503&#x2013;3518.</Citation></Reference><Reference><Citation>Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn&#x2019;s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: a randomised controlled trial. J Crohns Colitis. 2020;14:1049&#x2013;1056.</Citation></Reference><Reference><Citation>Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn&#x2019;s disease. Gut. 1980;21:525&#x2013;527.</Citation></Reference><Reference><Citation>Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation></Reference><Reference><Citation>Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn&#x2019;s disease: surgical treatment. J Crohns Colitis. 2020;14:155&#x2013;168.</Citation></Reference><Reference><Citation>Panes J, Garcia-Olmo D, Van Assche G, et al.; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation></Reference><Reference><Citation>Schwandner O. Stem cell injection for complex anal fistula in Crohn&#x2019;s disease: a single-center experience. World J Gastroenterol. 2021;27:3643&#x2013;3653.</Citation></Reference><Reference><Citation>Cabalzar-Wondberg D, Turina M, Biedermann L, Rogler G, Schreiner P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn&#x2019;s disease: a case series. Colorectal Dis. 2021;23:1444&#x2013;1450.</Citation></Reference><Reference><Citation>Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D; FATT Collaborative Group. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum. 2012;55:762&#x2013;772.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79&#x2013;86.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Herreros D, De-La-Quintana P, et al. Adipose-derived stem cells in Crohn&#x2019;s rectovaginal fistula. Case Rep Med. 2010;2010:961758.</Citation></Reference><Reference><Citation>Garcia-Arranz M, Herreros MD, Gonzalez-Gomez C, et al. Treatment of Crohn&#x2019;s-related rectovaginal fistula with allogeneic expanded-adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells Transl Med. 2016;5:1441&#x2013;1446.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn&#x2019;s disease. Expert Opin Biol Ther. 2008;8:1417&#x2013;1423.</Citation></Reference><Reference><Citation>Georgiev-Hristov T, Guadalajara H, Herreros MD, et al. A step-by-step surgical protocol for the treatment of perianal fistula with adipose-derived mesenchymal stem cells. J Gastrointest Surg. 2018;22:2003&#x2013;2012.</Citation></Reference><Reference><Citation>Kamal N, Motwani K, Wellington J, Wong U, Cross RK. Fecal incontinence in inflammatory bowel disease. Crohns Colitis 360. 2021;3:otab013.</Citation></Reference><Reference><Citation>Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn&#x2019;s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25:1054&#x2013;1060.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Garcia-Arranz M, Garcia LG, et al. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn&#x2019;s disease: a new cell-based therapy. Int J Colorectal Dis. 2003;18:451&#x2013;454.</Citation></Reference><Reference><Citation>Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn&#x2019;s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65:713&#x2013;720.</Citation></Reference><Reference><Citation>Zamora O, Baumgart DC, Faubion W, et al. P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn&#x2019;s disease and complex perianal fistulas. J Crohns Colitis. 2022;16:i536&#x2013;i537.</Citation></Reference><Reference><Citation>Borruel N, Mart&#xed; M, Armario D, et al. P297 Treatment of patients with complex perianal Crohn&#x2019;s disease with darvadstrocel: a single-institution real life experience. J Crohns Colitis. 2022;16:i326&#x2013;i327.</Citation></Reference><Reference><Citation>Elorza A, Arzallus T, Izagirre A, et al. P390 Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn&#x2019;s disease: multicentric experience in the Basque Country and Navarre. J Crohns Colitis. 2022;16:i388&#x2013;i388.</Citation></Reference><Reference><Citation>Dawoud C, Widmann KM, Czipin S, et al. Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn&#x2019;s disease&#x2014;a prospective nationwide multicenter cohort study. Wien Klin Wochenschr. 2023.</Citation></Reference><Reference><Citation>Fathallah N, Siproudhis L, Akaffou M, et al. Allogenic stem cells for Crohn&#x2019;s anal fistulas: treating early improves the deep remission rate. Colorectal Dis. 2023;25:2170&#x2013;2176.</Citation></Reference><Reference><Citation>Fathallah N, Akaffou M, Haouari MA, et al. Deep remission improves the quality of life of patients with Crohn&#x2019;s disease and anoperineal fistula treated with darvadstrocel: results of a French pilot study. Tech Coloproctol. 2023;27:1201&#x2013;1210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38039292</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Endoscopic Predictors of Residual Tumor After Total Neoadjuvant Therapy: A Post Hoc Analysis From the Organ Preservation in Rectal Adenocarcinoma Trial.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>376</EndPage><MedlinePgn>369-376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003096</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Restaging endoscopy plays a critical role in selecting patients with locally advanced rectal cancer who respond to neoadjuvant therapy for nonoperative management.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study evaluated the restaging endoscopic features that best predict the presence of residual tumor in the bowel wall.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a post hoc analysis of a prospective randomized trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The Organ Preservation in Rectal Adenocarcinoma Trial randomly assigned patients across 18 institutions with stage II/III rectal adenocarcinoma to receive either induction or consolidation total neoadjuvant therapy. Surgeons completed a restaging tumor assessment form, which stratified patients across 3 tiers of clinical response.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients enrolled in the Organ Preservation in Rectal Adenocarcinoma Trial with a completed tumor assessment form were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The main outcome was residual tumor, which was defined as either an incomplete clinical response or local tumor regrowth within 2 years of restaging. Independent predictors of residual tumor were identified using backward-selected multivariable logistic regression analysis. Subgroup analyses for complete and near complete clinical responders were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Surgeons completed restaging forms for 263 patients at a median of 7.7 weeks after neoadjuvant therapy; 128 patients (48.7%) had a residual tumor. On multivariable regression analysis, several characteristics of a near complete response, including ulcer (OR 6.66; 95% CI, 2.54-19.9), irregular mucosa (OR 3.66; 95% CI, 1.61-8.68), and nodularity (OR 2.96; 95% CI, 1.36-6.58), remained independent predictors of residual tumor. A flat scar was associated with lower odds of harboring residual disease (OR 0.32; 95% CI, 0.11-0.93) for patients categorized as clinical complete responders.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Limitations include analysis of endoscopic features at a single time point and ambiguities in tumor assessment form response criteria.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with ulcer, nodularity, or irregular mucosa, on restaging endoscopy have higher odds of residual tumor. Recognizing negative prognostic implications of these features will help surgeons better select candidates for nonoperative management and suggests that patients with high-risk characteristics would benefit from close interval surveillance. See Video Abstract .</AbstractText><AbstractText Label="PREDICTORES ENDOSCPICOS DE TUMOR RESIDUAL DESPUS DE TERAPIA NEOADYUVANTE TOTAL UN ANLISIS POST HOC DEL ENSAYO DE PRESERVACIN DE RGANOS EN ADENOCARCINOMA RECTAL" NlmCategory="UNASSIGNED">ANTECEDENTES:La reestadificaci&#xf3;n por endoscopia juega un papel cr&#xed;tico en la selecci&#xf3;n de pacientes con c&#xe1;ncer de recto localmente avanzado que responden a la terapia neoadyuvante para el manejo no quir&#xfa;rgico.OBJETIVO:Este estudio evalu&#xf3; las caracter&#xed;sticas endosc&#xf3;picas de reestadificaci&#xf3;n que mejor predicen la presencia de tumor residual en la pared intestinal.DISE&#xd1;O:Este fue un an&#xe1;lisis post hoc de un ensayo prospectivo aleatorizado.ESCENARIO:El ensayo Organ Preservation in Rectal Adenocarcinoma aleatoriz&#xf3; a pacientes de 18 instituciones con adenocarcinoma de recto en estadio II/III para recibir terapia neoadyuvante total de inducci&#xf3;n o consolidaci&#xf3;n. Los cirujanos completaron un formulario de reestadificaci&#xf3;n de evaluaci&#xf3;n del tumor, que estratific&#xf3; a los pacientes en tres niveles de respuesta cl&#xed;nica.PACIENTES:Se incluyeron pacientes inscritos en el ensayo de preservaci&#xf3;n de &#xf3;rganos en adenocarcinoma rectal con un formulario de evaluaci&#xf3;n del tumor completado.PRINCIPALES MEDIDAS DE RESULTADO:El resultado principal fue presencia de tumor residual, que se defini&#xf3; como una respuesta cl&#xed;nica incompleta o un nuevo crecimiento local del tumor dentro de los dos a&#xf1;os posteriores a la reestadificaci&#xf3;n. Los predictores independientes de tumor residual se identificaron mediante un an&#xe1;lisis de regresi&#xf3;n log&#xed;stica multivariable seleccionado hacia atr&#xe1;s. Se realizaron an&#xe1;lisis de subgrupos para pacientes con respuesta cl&#xed;nica completa y casi completa.RESULTADOS:Los cirujanos completaron formularios de reestadificaci&#xf3;n para 263 pacientes en una mediana de 7.7 semanas despu&#xe9;s de la terapia neoadyuvante; 128 (48.7%) ten&#xed;an tumor residual. En el an&#xe1;lisis de regresi&#xf3;n multivariable, varias caracter&#xed;sticas de una respuesta casi completa, incluyendo &#xfa;lcera (OR 6.66; IC 95% 2.54-19.9), mucosa irregular (OR 3.66; IC 95% 1.61-8.68) y nodularidad (OR 2.96; IC 95% 1.36 -6.58) siguieron siendo predictores independientes de tumor residual. Una cicatriz plana se asoci&#xf3; con menores probabilidades de albergar enfermedad residual (OR 0.32; IC del 95 %: 0.11-0.93) para los pacientes clasificados como respondedores cl&#xed;nicos completos.LIMITACIONES:Las limitaciones de este estudio incluyen el an&#xe1;lisis de las caracter&#xed;sticas endosc&#xf3;picas en un solo momento y las ambig&#xfc;edades en los criterios de respuesta.en la forma de evaluaci&#xf3;n del tumorCONCLUSIONES:Los pacientes con &#xfa;lcera, nodularidad o mucosa irregular en la endoscopia de reestadificaci&#xf3;n tienen mayores probabilidades de tumor residual. El reconocer las implicaciones pron&#xf3;sticas negativas de estas caracter&#xed;sticas ayudar&#xe1; a los cirujanos a seleccionar mejor a los candidatos para el tratamiento no quir&#xfa;rgico y sugiere que los pacientes con caracter&#xed;sticas de alto riesgo se beneficiar&#xed;an de una vigilancia a intervalos estrechos. (Traducci&#xf3;n-Dr. Jorge Silva Velazco ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8928-4190</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Hannah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Sabrina T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verheij</LastName><ForeName>Floris S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omer</LastName><ForeName>Dana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Li-Xuan</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Aguilar</LastName><ForeName>Julio</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2451-0948</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OPRA Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA182551</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009501</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004724" MajorTopicYN="N">Endoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018365" MajorTopicYN="N">Neoplasm, Residual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009926" MajorTopicYN="N">Organ Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014456" MajorTopicYN="N">Ulcer</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">La reestadificaci&#xf3;n de la endoscopia juega un papel cr&#xed;tico en la selecci&#xf3;n de pacientes con c&#xe1;ncer de recto localmente avanzado que responden a la terapia neoadyuvante para el manejo no quir&#xfa;rgico.</AbstractText><AbstractText Label="OBJETIVO:">Este estudio evalu&#xf3; las caracter&#xed;sticas endosc&#xf3;picas de reestadificaci&#xf3;n que mejor predicen la presencia de tumor residual en la pared intestinal.</AbstractText><AbstractText Label="DISE&#xd1;O:">Este fue un an&#xe1;lisis post hoc de un ensayo prospectivo aleatorizado.</AbstractText><AbstractText Label="AJUSTES:">El ensayo Organ Preservation in Rectal Adenocarcinoma aleatoriz&#xf3; a pacientes de 18 instituciones con adenocarcinoma de recto en estadio II/III para recibir terapia neoadyuvante total de inducci&#xf3;n o consolidaci&#xf3;n. Los cirujanos completaron un formulario de evaluaci&#xf3;n del tumor de reestadificaci&#xf3;n, que estratific&#xf3; a los pacientes en tres niveles de respuesta cl&#xed;nica.</AbstractText><AbstractText Label="PACIENTES:">Se incluyeron pacientes inscritos en el ensayo de preservaci&#xf3;n de &#xf3;rganos en adenocarcinoma rectal con un formulario de evaluaci&#xf3;n del tumor completado.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO:">El resultado principal fue el tumor residual, que se defini&#xf3; como una respuesta cl&#xed;nica incompleta o un nuevo crecimiento local del tumor dentro de los dos a&#xf1;os posteriores a la reestadificaci&#xf3;n. Los predictores independientes de tumor residual se identificaron mediante un an&#xe1;lisis de regresi&#xf3;n log&#xed;stica multivariable seleccionado hacia atr&#xe1;s. Se realizaron an&#xe1;lisis de subgrupos para pacientes con respuesta cl&#xed;nica completa y casi completa.</AbstractText><AbstractText Label="RESULTADOS:">Los cirujanos completaron formularios de reestadificaci&#xf3;n para 263 pacientes en una mediana de 7,7 semanas despu&#xe9;s de la terapia neoadyuvante; 128 (48,7%) ten&#xed;an tumor residual. En el an&#xe1;lisis de regresi&#xf3;n multivariable, varias caracter&#xed;sticas de una respuesta casi completa, incluyendo &#xfa;lcera (OR 6,66; IC 95% 2,54&#x2013;19,9), mucosa irregular (OR 3,66; IC 95% 1,61&#x2013;8,68) y nodularidad (OR 2,96; IC 95% 1,36 &#x2013;6,58) siguieron siendo predictores independientes de tumor residual. Una cicatriz plana se asoci&#xf3; con menores probabilidades de albergar enfermedad residual (OR 0,32; IC del 95 %: 0,11&#x2013;0,93) para los pacientes clasificados como respondedores cl&#xed;nicos completos.</AbstractText><AbstractText Label="LIMITACIONES:">Las limitaciones de este estudio incluyen el an&#xe1;lisis de las caracter&#xed;sticas endosc&#xf3;picas en un solo momento y las ambig&#xfc;edades en la evaluaci&#xf3;n del tumor en los criterios de respuesta.</AbstractText><AbstractText Label="CONCLUSIONES:">Los pacientes con &#xfa;lcera, nodularidad o mucosa irregular en la endoscopia de reestadificaci&#xf3;n tienen mayores probabilidades de tumor residual. Reconocer las implicaciones pron&#xf3;sticas negativas de estas caracter&#xed;sticas ayudar&#xe1; a los cirujanos a seleccionar mejor a los candidatos para el tratamiento no quir&#xfa;rgico y sugiere que los pacientes con caracter&#xed;sticas de alto riesgo se beneficiar&#xed;an de una vigilancia a intervalos estrechos. Consulte Video Resumen en http://links.lww.com/DCR/Bxxx. <i>(Pre-proofed version)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></OtherAbstract><InvestigatorList><Investigator ValidYN="Y"><LastName>Patil</LastName><ForeName>Sujata</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gollub</LastName><ForeName>Marc J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuval</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunne</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcet</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cataldo</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polite</LastName><ForeName>Blase</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herzig</LastName><ForeName>Daniel O</ForeName><Initials>DO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liska</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oommen</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friel</LastName><ForeName>Charles M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ternent</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coveler</LastName><ForeName>Andrew L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gregory</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varma</LastName><ForeName>Madhulika G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bello</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Joseph C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krauss</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gleisner</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paty</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiser</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>Garrett M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pappou</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillem</LastName><ForeName>Jos&#xe9; G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Temple</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wei</LastName><ForeName>Iris H</ForeName><Initials>IH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Widmar</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segal</LastName><ForeName>Neil H</ForeName><Initials>NH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cercek</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yaeger</LastName><ForeName>Rona</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>J Joshua</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodman</LastName><ForeName>Karyn A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Abraham J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saltz</LastName><ForeName>Leonard B</ForeName><Initials>LB</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>1</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>1</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38039292</ArticleId><ArticleId IdType="mid">NIHMS1944645</ArticleId><ArticleId IdType="pmc">PMC10922113</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003096</ArticleId><ArticleId IdType="pii">00003453-202403000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Juul T, Ahlberg M, Biondo S, et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum. 2014;57:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">24819098</ArticleId></ArticleIdList></Reference><Reference><Citation>Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251:807&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">20395841</ArticleId></ArticleIdList></Reference><Reference><Citation>Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis. Lancet Oncol. 2016;17:174&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">26705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362876</ArticleId><ArticleId IdType="pubmed">35483010</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">23154394</ArticleId></ArticleIdList></Reference><Reference><Citation>Haak HE, &#x17d;muc J, Lambregts DMJ, et al. The evaluation of follow-up strategies of watch-and-wait patients with a complete response after neoadjuvant therapy in rectal cancer. Colorectal Dis. 2021;23:1785&#x2013;1792.</Citation><ArticleIdList><ArticleId IdType="pubmed">33725387</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez LM, S&#xe3;o Juli&#xe3;o GP, Figueiredo NL, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch &amp; Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">33316218</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Valk MJM, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch &amp; Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537&#x2013;2545.</Citation><ArticleIdList><ArticleId IdType="pubmed">29976470</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas M, Lambregts DMJ, Nelemans PJ, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol. 2015;22:3873&#x2013;3880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595525</ArticleId><ArticleId IdType="pubmed">26198074</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sande ME, Beets GL, Hupkens BJ, et al. Response assessment after (chemo)radiotherapy for rectal cancer: why are we missing complete responses with MRI and endoscopy? Eur J Surg Oncol. 2019;45:1011&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">30528891</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sande ME, Maas M, Melenhorst J, et al. Predictive value of endoscopic features for a complete response after chemoradiotherapy for rectal cancer. Ann Surg. 2021;274:e541&#x2013;e547.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hupkens BJP, Maas M, Martens MH, et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response? Ann Surg Oncol. 2018;25:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">29134378</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Fernandez LM, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think! Dis Colon Rectum. 2019;62:802&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">31188180</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder SI, Patil S, Kennedy E, Garcia-Aguilar J. Endoscopic feature and response reproducibility in tumor assessment after neoadjuvant therapy for rectal adenocarcinoma. Ann Surg Oncol. 2021;28:5205&#x2013;5223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8355052</ArticleId><ArticleId IdType="pubmed">33796995</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahas SC, Nahas CSR, Marques CFS, et al. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of Watch-and-Wait treatment of rectal cancer. Dis Colon Rectum. 2016;59:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">26953983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura A, Chino A, Konishi T, et al. Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response. Int J Colorectal Dis. 2015;30:367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">25566952</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith FM, Chang KH, Sheahan K, et al. The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg. 2012;99:993&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">22351592</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith FM, Wiland H, Mace A, et al. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57:311&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">24509452</ArticleId></ArticleIdList></Reference><Reference><Citation>Habr-Gama A, Perez RO, Wynn G, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692&#x2013;1698.</Citation><ArticleIdList><ArticleId IdType="pubmed">21178866</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson H, Kim JK, Yuval JB, et al. Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial. J Clin Oncol. 2021;39(suppl):3509.</Citation></Reference><Reference><Citation>Smith JJ, Chow OS, Gollub MJ, et al. Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4619249</ArticleId><ArticleId IdType="pubmed">26497495</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams H, Thompson H, Lin S, Verheij F, Qin L, Garcia-Aguilar J. Endoscopic predictors of residual tumor after total neoadjuvant therapy: a post hoc analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial [ASCRS abstract M10]. Dis Colon Rectum. 2023;66:e378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10922113</ArticleId><ArticleId IdType="pubmed">38039292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerd&#xe1;n-Santacruz C, Vailati BB, S&#xe3;o Juli&#xe3;o GP, et al. Watch and wait: why, to whom and how. Surg Oncol. 2022;43:101774.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491334</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens MH, Maas M, Heijnen LA, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108:djw171.</Citation><ArticleIdList><ArticleId IdType="pubmed">27509881</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sande ME, Figueiredo N, Beets GL. Management and outcome of local regrowths in a Watch-and-Wait prospective cohort for complete responses in rectal cancer. Ann Surg. 2021;274:e1056&#x2013;e1062.</Citation><ArticleIdList><ArticleId IdType="pubmed">32039985</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith JJ, Strombom P, Chow OS, et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5:e185896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459120</ArticleId><ArticleId IdType="pubmed">30629084</ArticleId></ArticleIdList></Reference><Reference><Citation>Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pubmed">28479372</ArticleId></ArticleIdList></Reference><Reference><Citation>Fokas E, Allg&#xe4;uer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212&#x2013;3222.</Citation><ArticleIdList><ArticleId IdType="pubmed">31150315</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>